An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease

Trial Profile

An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Venglustat (Primary)
  • Indications Fabry's disease
  • Focus Adverse reactions
  • Sponsors Sanofi; Sanofi Genzyme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 26 May 2016 Planned End Date changed from 1 Mar 2019 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top